<p>This is a summary of the European public assessment report (EPAR) for Nevanac. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nevanac.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Nevanac is indicated for:</p> <ul><li>prevention and treatment of postoperative pain and inflammation associated with cataract surgery;</li> <li>reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
S01BC10
ATC Item
N/A
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nepafenac | N/A | nepafenac |
EMA Name
Nevanac
Medicine Name
Nevanac
Aliases
N/ANo risk management plan link.
